Hyperbilirubinemia, conjugated, type 3

Summary

Hyperbilirubinemia, conjugated, type 3 (MONDO:0009381) is a disease. A subtype of hereditary hyperbilirubinemia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	hyperbilirubinemia, conjugated, type 3
Mondo ID	MONDO:0009381
MeSH	C562885
OMIM	237550
SNOMED CT	235906009
UMLS	C0400964
MedGen	98323
GARD	0024667
Is cancer (heuristic)	no

Disease family

This is a subtype of hereditary hyperbilirubinemia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › inborn errors of metabolism › inborn disorder of porphyrin metabolism › inborn disorder of bilirubin metabolism › hereditary hyperbilirubinemia › hyperbilirubinemia, conjugated, type 3

Related subtypes (6): Gilbert syndrome, Crigler-Najjar syndrome, Rotor syndrome, Dubin-Johnson syndrome, hyperbilirubinemia, shunt, primary, transient familial neonatal hyperbilirubinemia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.